Renaissance Technologies
BBOT

Renaissance Technologies’s BridgeBio Oncology BBOT Stock Holding History

Renaissance Technologies’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$912K Buy
101,900
+27,600
+37% +$296K ﹤0.01% 2319
2025
Q4 		$930K Buy
+74,300
New +$900K ﹤0.01% 2324

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies's BBOT Position: Q1 2026 in Review

Renaissance Technologies increased its BridgeBio Oncology (BBOT) stake by 37% in Q1 2026, buying an estimated $296K and bringing the position to 101,900 shares worth $912K. The position accounts for ﹤0.01% of the portfolio, ranked #2319.

Renaissance Technologies first reported a position in BBOT in Q4 2025 and has held it in 2 quarters since. The position peaked at $930K in Q4 2025. 67 funds tracked by Wall St. Rank hold BBOT as of Q1 2026.

  • Renaissance Technologies held 101,900 shares of BridgeBio Oncology worth $912K as of Q1 2026.
  • Renaissance Technologies bought 27,600 BridgeBio Oncology shares in Q1 2026, an estimated $296K.
  • BridgeBio Oncology made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2319 holding.
  • Renaissance Technologies first reported a position in BridgeBio Oncology in Q4 2025 and has held it in 2 quarters since.
  • Renaissance Technologies's BridgeBio Oncology position peaked at $930K in Q4 2025.
  • 67 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.